A short report says Novo's amycretin produced notable weight loss. No trial figures are given, so tap through for the numbers.
Recap by typeshit. Full story at Meteo.gr.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Attia's team challenges the claim that peptides like BPC-157 and TB-500 can't be patented, mapping each compound's patent and drug development history.
Liz walks through everything she eats on a weekend while taking Wegovy, including a meal out at a restaurant.
Loading…